Subtopic Deep Dive
Neuroendocrine Tumor Epidemiology
Research Guide
What is Neuroendocrine Tumor Epidemiology?
Neuroendocrine Tumor Epidemiology studies the incidence, prevalence, survival rates, and demographic patterns of neuroendocrine tumors using population-based registries like SEER.
This field documents rising NET incidence from 35,825 U.S. cases analyzed by Yao et al. (2008, 4468 citations), showing increased diagnoses over a century. Dasari et al. (2017, 3354 citations) reported steady rises in incidence and prevalence with improved survival, particularly for gastrointestinal and pancreatic NETs. Geographic and demographic disparities guide research priorities.
Why It Matters
Epidemiologic data from Yao et al. (2008) inform resource allocation for rising NET cases, influencing screening programs. Dasari et al. (2017) trends highlight survival gains for distant-stage tumors, prioritizing therapies like those in Strosberg et al. (2017). Demographic insights from SEER registries address disparities, optimizing clinical trial designs and public health strategies.
Key Research Challenges
Rising Incidence Attribution
Distinguishing true NET incidence increases from detection biases challenges researchers. Yao et al. (2008) noted diagnostic improvements over 30 years in 35,825 cases. Dasari et al. (2017) linked rises to early-stage detection and stage migration.
Survival Heterogeneity Analysis
Variations in NET survival by site, stage, and demographics complicate prognostic modeling. Dasari et al. (2017) showed gains mainly in gastrointestinal and pancreatic NETs. Yao et al. (2008) identified prognostic factors across tumor locations.
Registry Data Comparability
Harmonizing SEER with global registries reveals geographic disparities but faces coding inconsistencies. Yao et al. (2008) used U.S. SEER for comprehensive epidemiology. International comparisons remain limited in scope.
Essential Papers
One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
James C. Yao, Manal M. Hassan, Alexandria T. Phan et al. · 2008 · Journal of Clinical Oncology · 4.5K citations
Purpose Neuroendocrine tumors (NETs) are considered rare tumors and can produce a variety of hormones. In this study, we examined the epidemiology of and prognostic factors for NETs, because a thor...
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
Arvind Dasari, Chan Shen, Daniel M. Halperin et al. · 2017 · JAMA Oncology · 3.4K citations
The incidence and prevalence of NETs are steadily rising, possibly owing to detection of early-stage disease and stage migration. Survival for all NETs has improved over time, especially for distan...
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna et al. · 2018 · New England Journal of Medicine · 3.3K citations
The addition of atezolizumab to chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer resulted in significantly longer overall survival and progression-free survival th...
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin et al. · 2017 · New England Journal of Medicine · 3.0K citations
Treatment with <sup>177</sup>Lu-Dotatate resulted in markedly longer progression-free survival and a significantly higher response rate than high-dose octreotide LAR among patients with advanced mi...
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
James C. Yao, Manisha H. Shah, Tetsuhide Ito et al. · 2011 · New England Journal of Medicine · 2.8K citations
Everolimus, as compared with placebo, significantly prolonged progression-free survival among patients with progressive advanced pancreatic neuroendocrine tumors and was associated with a low rate ...
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Éric Raymond, Laëtitia Dahan, Jean‐Luc Raoul et al. · 2011 · New England Journal of Medicine · 2.5K citations
Continuous daily administration of sunitinib at a dose of 37.5 mg improved progression-free survival, overall survival, and the objective response rate as compared with placebo among patients with ...
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Anja Rinke, Hans‐Helge Müller, Carmen Schade‐Brittinger et al. · 2009 · Journal of Clinical Oncology · 2.5K citations
Purpose Somatostatin analogs are indicated for symptom control in patients with gastroenteropancreatic neuroendocrine tumors (NETs). The ability of somatostatin analogs to control the growth of wel...
Reading Guide
Foundational Papers
Start with Yao et al. (2008) for comprehensive U.S. NET epidemiology in 35,825 cases and prognostic factors. Follow with Rinke et al. (2009) for midgut tumor control data informing survival baselines.
Recent Advances
Study Dasari et al. (2017) for incidence/prevalence trends and survival improvements. Review Strosberg et al. (2017) for midgut NET therapy impacts on epidemiology.
Core Methods
SEER registry queries for incidence rates; Kaplan-Meier survival analysis; Cox proportional hazards for prognostics, as in Yao et al. (2008) and Dasari et al. (2017).
How PapersFlow Helps You Research Neuroendocrine Tumor Epidemiology
Discover & Search
Research Agent uses searchPapers and citationGraph on Yao et al. (2008) to map 4468 citing papers tracking NET trends. exaSearch queries 'SEER neuroendocrine tumor incidence 2000-2020' for recent registry data. findSimilarPapers expands to Dasari et al. (2017) for prevalence studies.
Analyze & Verify
Analysis Agent applies readPaperContent to extract incidence rates from Dasari et al. (2017), then runPythonAnalysis with pandas to plot survival trends from SEER tables. verifyResponse (CoVe) checks claims against Yao et al. (2008); GRADE grading scores evidence as high for U.S. epidemiology.
Synthesize & Write
Synthesis Agent detects gaps in geographic data beyond SEER using contradiction flagging on Yao et al. (2008) vs. Dasari et al. (2017). Writing Agent employs latexEditText for epidemiology tables, latexSyncCitations for 10+ papers, and latexCompile for review manuscripts; exportMermaid visualizes incidence timelines.
Use Cases
"Plot NET incidence trends from SEER data in Yao and Dasari papers using Python."
Research Agent → searchPapers('NET SEER epidemiology') → Analysis Agent → readPaperContent(Yao 2008) + readPaperContent(Dasari 2017) → runPythonAnalysis(pandas plot incidence vs. year) → matplotlib survival curve output.
"Draft LaTeX review on NET survival improvements with citations."
Research Agent → citationGraph(Yao 2008) → Synthesis Agent → gap detection → Writing Agent → latexEditText(structured review) → latexSyncCitations(10 papers) → latexCompile(PDF with figures).
"Find code for analyzing NET registry data from papers."
Research Agent → searchPapers('NET epidemiology code SEER') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis(sandbox test on extracted scripts for incidence modeling).
Automated Workflows
Deep Research workflow synthesizes 50+ NET epidemiology papers into structured reports: searchPapers → citationGraph → GRADE all claims. DeepScan applies 7-step analysis to Yao et al. (2008) with CoVe checkpoints for incidence accuracy. Theorizer generates hypotheses on rising trends from Dasari et al. (2017) data.
Frequently Asked Questions
What defines Neuroendocrine Tumor Epidemiology?
It examines NET incidence, prevalence, survival, and demographics using SEER and registries, as in Yao et al. (2008) analyzing 35,825 U.S. cases.
What methods track NET trends?
SEER database analyses quantify incidence and survival; Yao et al. (2008) used 1973-2004 data, Dasari et al. (2017) extended to 2012 showing rises.
What are key papers?
Yao et al. (2008, 4468 citations) provides foundational U.S. epidemiology; Dasari et al. (2017, 3354 citations) details incidence/prevalence trends.
What open problems exist?
Attributing incidence rises to biology vs. detection; global registry harmonization beyond SEER; demographic disparity mechanisms.
Research Neuroendocrine Tumor Research Advances with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Neuroendocrine Tumor Epidemiology with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers